IP Library Patent Application 14525381
Patent Application
App. No. 14/525,381

SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/525,381
Abstract

The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

Claims (14)

1 - 34 . (canceled)

35 . A method of inhibiting tumor growth in a patient comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt, or a hydrate or solvate thereof.

36 . A method of inhibiting tumor metastasis in a patient comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt, or a hydrate or solvate thereof.

37 . A method of treating cancer in a patient, wherein said cancer is associated with dysregulation of the HGF/c-MET signaling pathway, comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt, or a hydrate or solvate thereof.

38 . (canceled)

39 . A method of treating a cancer in a patient comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt, or a hydrate or solvate thereof wherein said cancer is lung cancer, liver cancer, colorectal cancer, gastric cancer, glioblastoma, breast cancer, or cancer of the kidney.

40 - 83 . (canceled)

84 . The method of claim 39 , wherein said cancer is lung cancer.

85 . The method of claim 39 , wherein said cancer is liver cancer.

86 . The method of claim 39 , wherein said cancer is colorectal cancer.

87 . The method of claim 39 , wherein said cancer is gastric cancer.

88 . The method of claim 39 , wherein said cancer is glioblastoma.

89 . The method of claim 39 , wherein said cancer is breast cancer.

90 . The method of claim 39 , wherein said cancer is cancer of the kidney.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2015
From: WENG, LINGKAI; QIAO, LEI; ZHOU, JIACHENG; LIU, PINGLI; PAN, YONGCHUN
To: INCYTE CORPORATION
Reel/Frame 036080/0364 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY INFORMATION PREVIOUSLY RECORDED ON REEL 035920 FRAME 0576. ASSIGNOR(S) HEREBY CONFIRMS THE RECEIVING PARTY NAME SHOULD BE RECORDED AS TWO PARTIES. Recorded Jul 2, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 036054/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION
Reel/Frame 035920/0576 →